

**Nona Giornata Fiorentina
dedicata ai pazienti con
malattie mieloproliferative
croniche**


Sabato 20 maggio 2023

“Introduzione alla mielofibrosi”

Giovanni Barosi

***Centro per lo Studio della Mielofibrosi
IRCCS Policlinico S. Matteo, Pavia***





ISTITUTO DI PATOLOGIA MEDICA DELL'UNIVERSITÀ DI MODENA
DIRETTORE: PROF. EDOARDO STORTI

LA MIELOFIBROSI IDIOPATICA
ASPETTI CLINICI, FISIOPATOLOGICI E TERAPEUTICI

EDOARDO STORTI - SERGIO PERUGINI

con la collaborazione di:



MAURI C. - ASCARI E. - SILINGARDI V. - STERNIERI E. - MUCCI P. - LUSVARGHI E.
FONTANA G. - PATRIGNANI A. - QUAGLINO D. - SAULI S. - EMILIA G. - BARBOLINI G.
ARTUSI T. - TRALDI A. - BALDUINI C. - DAVOLI L.

Estratto da: *Atti del XXI Congresso Nazionale
della Società Italiana di Ematologia*
Modena 10-11 giugno 1967

Tipografia Viscontea, Corso A. Manzoni, 41 - Pavia
1968

La mielofibrosi negli anni 70

Splenomegalia
Fibrosi midollare
Emazie a lacrima



The Italian Diagnostic Criteria of MMM (1999)

Necessary criteria

- A. Diffuse bone marrow fibrosis
- B. Absence of Philadelphia chromosome or BCR-ABL rearrangement in peripheral blood cells

Optional criteria

1. Splenomegaly of any grade
2. Anisopoikilocytosis with tear-drop erythrocytes
3. Presence of circulating immature myeloid cells
4. Presence of circulating erythroblasts
5. Presence of clusters of megakaryoblasts and anomalous megakaryocytes in bone marrow sections
6. Myeloid metaplasia

Diagnosis of MMM:

The two necessary criteria plus any other 2 optional criteria when splenomegaly is present, or any other 4 optional criteria when splenomegaly is absent

WHO diagnostic criteria for myelofibrosis (2016)

Prefibrotic/early stage

Major criteria

- 1. Megakaryocyte proliferation and atypia, without reticulin fibrosis grade >1, accompanied by increased age-adjusted BM cellularity, granulocytic proliferation, and (often) decreased erythropoiesis*
- 2. Not meeting WHO criteria for other myeloid neoplasms*
- 3. JAK2, CALR, or MPL mutation, or presence of another clonal marker*

Fibrotic stage

Major criteria

- 1. Megakaryocyte proliferation and atypia, accompanied by reticulin and/or collagen fibrosis grade 2 or 3*
- 2. Not meeting WHO criteria for other myeloid neoplasms*
- 3. JAK2, CALR, or MPL mutation, or presence of another clonal marker*

